Publication :
Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life : study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial

Notice brève
ali.license-refhttps://creativecommons.org/licenses/by/4.0fr
ali.license-ref.start-date2019-08-09fr
bul.description.provenancelf spbfr
bul.rights.dateAccepPubl2018-01-10fr
bul.rights.periodeEmbargoP0Mfr
bul.rights.typeDatedatePublicationfr
dc.contributor.authorDuchesne, Thierry
dc.contributor.authorSavard, Josée
dc.contributor.authorGuertin, Marie-Hélène
dc.contributor.authorFradet, Vincent
dc.contributor.authorPelletier, Jean-François
dc.contributor.authorBairati, Isabelle
dc.contributor.authorJulien, Pierre
dc.contributor.authorRobitaille, Karine
dc.date.accessioned2019-08-13T14:28:27Z
dc.date.available2019-08-13T14:28:27Z
dc.date.issued2018-01-10
dc.description.abstractBackground : Prostate cancer is the most commonly diagnosed cancer in north-American men. Few dietary or lifestyle interventions have been tested to prevent prostate cancer progression. Omega-3 fatty acid supplementation represents a promising intervention for prostate cancer patients. The aim of the study is to evaluate the effects of long-chain omega-3 polyunsaturated fatty acids (LCn3), more precisely eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation, on prostate cancer proliferation, inflammation mediators and quality of life among men who will undergo radical prostatectomy. Methods/design : We propose a phase IIb, randomized, double-blind placebo-controlled trial of MAG-EPA supplementation for 130 men who will undergo radical prostatectomy as treatment for a prostate cancer of Gleason score ≥ 7 in an academic cancer center in Quebec City. Participants will be randomized to 6 capsules of 625 mg of fish oil (MAG-EPA) per capsule containing 500 mg of EPA daily or to identically looking capsules of high oleic acid sunflower oil (HOSO) as placebo. The intervention begins 4 to 10 weeks prior to radical prostatectomy (baseline) and continues for one year after surgery. The primary endpoint is the proliferative index (Ki-67) measured in prostate cancer cells at radical prostatectomy. A secondary endpoint includes prostate tissue levels of inflammatory mediators (cytokines and proteins) at time of radical prostatectomy. Changes in blood levels of inflammatory mediators, relative to baseline levels, at time of radical prostatectomy and 12 months after radical prostatectomy will also be evaluated. Secondary endpoints also include important aspects of psychosocial functioning and quality of life such as depression, anxiety, sleep disturbances, fatigue, cognitive complaints and prostate cancer-specific quality of life domains. The changes in these outcomes, relative to baseline levels, will be evaluated at 3, 6, 9 and 12 months after radical prostatectomy. Discussion : The results from this trial will provide crucial information to clarify the role of omega-3 supplementation on prostate cancer proliferation, inflammation and quality of life.fr
dc.identifier.doi10.1186/s12885-017-3979-9fr
dc.identifier.issn1471-2407fr
dc.identifier.pubmed29321047fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/35934
dc.languageengfr
dc.publisherBioMed Centralfr
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subjectProstate cancerfr
dc.subjectOmega-3fr
dc.subjectProliferationfr
dc.subjectInflammationfr
dc.subjectQuality of lifefr
dc.subject.rvmProstate -- Cancerfr
dc.subject.rvmAcides gras oméga 3fr
dc.subject.rvmQualité de la viefr
dc.subject.rvmCellules cancéreuses -- Proliférationfr
dc.subject.rvmProstatectomiefr
dc.subject.rvmInflammation (Pathologie)fr
dc.titleEffects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life : study protocol for a phase IIb, randomized, double-blind, placebo-controlled trialfr
dc.typearticle de recherche
dc.type.legacyCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationBMC cancer, Vol. 18 (64), 1-10 (2018)fr
dspace.accessstatus.time2023-05-25 18:32:34
dspace.entity.typePublication
relation.isAuthorOfPublication338165ed-d68a-4d6a-827d-59e32d424538
relation.isAuthorOfPublication4bd3d74a-df24-4503-a65b-4658c9dd3a1f
relation.isAuthorOfPublication647d55e8-c458-45d3-85fb-8d4a0003f0f1
relation.isAuthorOfPublication8a1a02df-2ed5-410a-b69b-ee06f8551267
relation.isAuthorOfPublication9c32939c-87bd-4dd7-8c88-4d0da34dada0
relation.isAuthorOfPublicationc2778755-dc01-4734-adc5-5a88ad7dc380
relation.isAuthorOfPublicationd96d8f79-88a3-4e54-97a5-a6a4b854d838
relation.isAuthorOfPublicationdd26bc6f-dd6c-448f-b6f3-721ffe5a69e9
relation.isAuthorOfPublication.latestForDiscovery338165ed-d68a-4d6a-827d-59e32d424538
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.project.funder-nameLotte and John Hecht Memorial Foundationfr
rioxxterms.project.funder-nameCanadian Cancer Society Research Institutefr
rioxxterms.project.funder-nameSCF Pharma and Solutexfr
rioxxterms.versionVersion of Record (VoR)fr
rioxxterms.version-of-recordhttps://doi.org/10.1186/s12885-017-3979-9fr
Fichiers
Bundle original
Voici les éléments 1 - 1 sur 1
Vignette d'image
Nom :
Guertin, M.-H., Robitaille, K., Pelletier, J.-F., Duchesne, T., Julien, P., Savard, J., Bairati, I., & Fradet, V. (2018).pdf
Taille :
611.17 KB
Format :
Adobe Portable Document Format
Description :
Télécharger
Collections
Articles publiés dans des revues avec comité de lecture